NICE recommends Novartis Cosentyx® (secukinumab) as the

NICE recommends Novartis Cosentyx® (secukinumab) as the first biologic treatment for hidradenitis suppurativa (HS) since 2016 •    Hidradenitis suppurativa (HS) is a painful, chronic and progressive inflammatory skin disease with over 50% of people reporting a mental health impact1,2 &bu...

Related Keywords

London , City Of , United Kingdom , Ireland , British , Dermatol Venereol , Novartis Cosentyx , Phil Brady , Hidradenitis Suppurativa , Acta Derm Venereol , John Ingram , Novartis Pharmaceuticals Corp , Treatment Fund , Innovative Medicines Fund , Twitter , British Skin Foundation , Novartis , Treatment Fund In Wales , Novartis Pharmaceuticals United Kingdom Ltd , National Institute For Health , National Institute , Care Excellence , New Treatment Fund , Clinical Reader , Consultant Dermatologist , Chief Operating Officer , British Skin , Hidradenitis Suppurativa Clinical Response , Country President , Novartis Innovative Medicines United Kingdom , Novartis United Kingdom , Final Draft Guidance , Novartis Pharmaceuticals United Kingdom , Rev Dis , Its Effect , Two Secukinumab Dose Regimens , Subjects With Moderate , Severe Hidradenitis Suppurativa , Provides Sustained Improvements , Psoriatic Arthritis , Pooled Safety , Pharmaceuticals Corp , Secukinumab Over Five Years , Moderate To Severe Plaque Psoriasis , Ankylosing Spondylitis , Integrated Pooled Clinical Trial , Post Marketing Surveillance , Acta Derm ,